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Received January 13, 2015; accepted February 14, 2015AbstractFrom a hemodynamic point of view, hepatic vascular resistance and portal inflow determine the level of portal pressure. Factors that
determine hepatic vascular resistance include both structural and dynamic components. Among the structural components are histological
characteristics such as steatosis, fibrosis, regeneration nodules, and neo-angiogenesis. Dynamic structures include cells with contractile prop-
erties such as hepatocytes, hepatic stellate cells, sinusoidal endothelial cells, and Kupffer cells. The contributions of the interactions between
four cells in cirrhotic livers resulted in hepatic endothelial dysfunction, hepatic microcirculatory dysfunction, hepatic venous dysregulation,
hepatic fibrogenesis, and subsequently increased intrahepatic resistance and portal hypertension in cirrhosis. The pathogenic mechanisms that
trigger the associated abnormalities in hepatic microcirculations include persistent endotoxemia, increased hepatic oxidative stress, activated
endocannabinoids substances, pathogenic sinusoidal remodeling, and hypoperfusion in cirrhotic livers. Cumulative data suggested that various
therapeutic strategies targeting hepatic microcirculation provided effective improvement of the systemic abnormalities of cirrhosis. Accordingly,
the mechanistic and therapeutic approaches focusing on the disarrangement of hepatic microcirculation will be introduced in this article.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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intrahepatic resistance in cirrhotic livers
Increased intrahepatic resistance (IHR) is an initial event in
the development of portal hypertension (PH) in cirrhosis.1e4
Portal hypertension has traditionally been viewed as a pro-
gressive process, involving ultrastructural changes including
fibrosis, nodule formation, and vascular thrombosis, leading to
an increased intrahepatic resistance to flow.1e4 Recent studies
have demonstrated that there are contractile elements in
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(Figure 1).5e8 Chronic liver injury can activate Kupffer cells
(KCs), sinusoidal endothelial cells (SECs), and hepatic stellate
cells (HSCs) to modulate hepatic blood flow, IHR, and hepatic
fibrogenesis.5,7,9,10 In particular, HSCs contract and proliferate
to regulate the microvascular tone in response to vasocon-
strictors or vasodilators and increase extracellular matrix
production in cirrhotic livers.9,10
It has been increasingly recognized that the dynamic
component of cirrhotic livers was regulated by complex in-
teractions between the injured hepatocytes, the SECs, the KCs,
and the HSCs, which impact sinusoidal caliber. A recent study
suggested that systemic inflammation and portal hypertension
are linked by endothelial dysfunction and innate immune in-
teractions within the sinusoidal niche of the injured liver.11
Moreover, recent findings suggest these hemodynamic find-
ings are most marked in patients with superimposed
inflammation.ociation. All rights reserved.
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Figure 1. The illustration of the mechanistic components of increased intrahepatic resistance (IHR) in cirrhotic livers.
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In cirrhotic livers, the microcomputed tomography-based
evaluation of hepatic microvasculatures revealed the
increased abnormal neo-angiogenesis which is characterized
by distorted vessels of varying diameter that impair sinusoidal
perfusion and promote hepatic fibrogenesis.10e15 In fact,
activated HSCs secrete angiopoietin-1 to promote interactions
between HSCs and SECs and lead to fibrosis-associated
angiogenesis and sinusoidal remodeling in cirrhotic liv-
ers.15e20 Meanwhile, activation of KCs is accompanied by
increased inflammatory cytokine and chemokine release which
further stimulates HSC/SEC and angiogenesis.21 Inflammatory
mediators accelerate angiogenesis to maintain the chronic
inflammatory state in the tissue by transporting leukocytes and
supplying nutrients/oxygen. Subsequently, angiogenesis-
related increased endothelial surface area creates an enor-
mous capacity for inflammatory cytokines and adhesion
molecules productions. Actually, all fibrogenic and inflam-
matory markers measured in our study were also classified as
angiogenic factors due to their ability to stimulate the vascular
endothelial growth factor (VEGF) production from vascular
endothelial cells and inflammatory cells.22e25
Angiogenesis is regulated by the net balance of proangio-
genic factors and angiogenic inhibitors. To date, many positive
and negative angiogenic-modulating factors have been iden-
tified. Among these, VEGF and fibroblast growth factor (FGF)
are the most potent factors in neo-angiogenesis.25,26 VEGF is
not only an angiogenic factor, it is also known as a survival
factor for SECs. VEGF and FGF expression increases stepwise
during liver fibrosis development and suppression of the
VEGF/FGF signaling cascade attenuates these pathologic se-
quences.25,26 It has become increasingly evident that VEGFand FGF expression are a common response to liver
injury.25,26 Increased serum and hepatic VEGF and FGF levels
had been reported in cirrhosis.27,28 During hepatic fibro-
genesis, FGF-2 mediates the mitogenic effects of transforming
growth factor-beta1 (TGFb1) for HSCs.
18,28 Impaired sinu-
soidal perfusion, intrahepatic shunt, and capillarization of the
sinusoids, leading to hypoxia stress, VEGF expression, and
angiogenesis in fibrotic livers.29,30 Further studies suggest that
FGF-2 and TGFb1 synergistic with hypoxia stress to stimulate
VEGF expression.25,29,30e32
In experimental models of PH, coordination between
VEGF and FGF-2 initiate and maintain hyperdynamic sys-
temic and splanchnic circulations.25,29,30,32 Accordingly,
chronic anti-VEGF and FGF targeting therapy attenuates he-
patic fibrogenesis, improved hepatic blood flow and associated
portal hypertensive syndrome in cirrhotic rats.10,12e14,33,34
3. Hepatic venous dysregulation in cirrhosis
Under normal conditions, the hepatic vein is well able to
accommodate acute increased splanchnic blood volume, such
as variceal bleeding and food intake, and still keep the portal
venous pressure (PVP) at normal levels.8,35e37 However, an
immediately abnormal increase in PVP induced by acute
increased splanchnic blood volume (hepatic venous dysregu-
lation) results from improper dilatation of poor-compliance
intrahepatic microvasculatures (abnormal neo-angiogenic he-
patic microvessels) in NASH-cirrhotic PH rats.10 So, repeated
postprandial-increased PVP may aggravate progressive dila-
tion of portal-systemic collateral and varices that eventually
lead to variceal bleeding in cirrhosis.38 It has been shown that
blood infusion after controlled hemorrhage and hemodynamic
stabilization in cirrhotic rats but not in normal rats causes a
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pressure returns to normal.37
Exaggerated splanchnic vasodilatation/hyperemia and
increased portal blood flow and PVP (hepatic venous dysre-
gulation) are mainly mediated by nitric oxide (NO) over-
production in cirrhosis.12,37,39 NO donors have been reported
to improve postprandial hyperemia.39 In cirrhotic PH patients
with varices, attenuation of NO-mediated postprandial hy-
peremia, increased portal blood flow, and PVP should also
depend on the improvement in the compliance of intrahepatic
microvasculatures. Remarkably, anti-VEGFR agents improve
hepatic venous dysregulation through the suppression of
abnormal hepatic neo-angiogenesis and VEGF-eNOS-NO
cascades. These anti-VEGFR-related effects further prevent
the elevation of PVP secondary to transfusion and food intake-
increased portal blood flow in cirrhosis.10 Clinically, the above
beneficial effects of anti-VEGFR agents might reduce the risk
of rebleeding in cirrhotic patients after hemodynamic stabili-
zation by controlling variceal bleeding.
4. Cirrhotic livers are characterized by vasodilator
hyporesponsiveness and vasoconstrictor hyper-
responsiveness
Under normal physiological conditions, vascular tone is
maintained by the balance between the activity of vasodilators
and vasoconstrictors.5e8,40e43 Previous studies had demon-
strated that increased IHR in cirrhosis is caused by the
decrease in endothelium-dependent vasodilators (such as NO)
and the increase in endothelium-dependent vasoconstrictors
[such as endothelin-1 (ET-1), angiotensin II (Ang II), throm-
boxanes, and endocannabinoids] in liver.5e8,40e434.1. Hepatic endothelial dysfunction-vasodilators (NO)
hyporesponsivenessOxidative stress is defined as a loss of the physiologic
equilibrium due to increased ROS production and/or decreased
antioxidants.44,45 Indeed, increased oxidative stress had been
documented during cirrhosis, fully developed cirrhosis, and
following the development of cirrhosis.44e46 NO is a critical
vasodilator which modulates IHR.39e41,43 An impaired
endothelium-dependent response to vasodilators, which is
called hepatic endothelial dysfunction (HED), due to a
reduction in NO bioavailability has been noted in cirrhotic
livers.39e41,43 So, any therapeutic approach improving intra-
hepatic NO bioavailability is clinically relevant and thus suf-
ficiently important for the treatment of PH.45,47 Abraldes
et al47 had reported that administration of simvastatin can
decrease IHR through increasing hepatic NO in cirrhotic rats.
Furthermore, it has been reported that increased oxidative
stress is involved in the depletion of NO and the development
of HED in cirrhotic livers.39e41,43
Cumulative studies had suggested that chronic adminis-
tration of antioxidants N-acetylcysteine, ursodeoxycholic
acid, and vitamin E can suppress hepatic oxidative stress,
therefore increases NO bioavailability to improve HED anddecrease IHR in cirrhotic rats.39e41,43 Recent studies also
revealed that chronic administration of liver specific NO
donor-NCX-100 and antioxidants markedly decrease hepatic
collagen deposition, IHR and portal pressure in cirrhotic
animals.39e41,43,48,49
5. HED-vasoconstrictors hyper-responsiveness
(1) ET-1
ET-1 is a potent vasoconstrictor involved in the regulation
of hepatic microcirculation and in the development of PH.7,50
Remarkably, hepatic ET-1 is overexpressed in human and rat
cirrhotic livers to induce HSCs contraction and increased
IHR.7,50,51 In PH rat livers, pre-incubation with an endothelin
receptor type A (ETAR) antagonist markedly abolished the ET-
1-induced increased IHR.50,51
(2) Angiotensin II
As IHR increases, the increased portal resistance results in
dilatation of the mesenteric and systemic vasculatures and de-
creases the effective blood volume. A compensatory change that
restores the effective blood volume is the activation of the renin-
angiotensin-aldosterone system (RAS).8,52e55 The RAS plays
an important role in the regulation of local hemodynamics in
cirrhotic livers.52 The primary effector peptide of the system is
angiotensin II (Ang II).47,52 Administration of Ang II receptor
blockers decreased the IHR of cirrhotic rat livers.3,8,52 Renin,
which cleaves liver-produced angiotensinogen to Ang I, is the
first rate-limiting enzyme in the synthesis ofAng II. Inhibition of
renin activity has been a potential way to downregulate the RAS.
A recent study reported that acute administration of aliskiren, a
direct renin inhibitor, reduced IHR and portal pressure by
amelioration of the Ang II-induced intrahepatic vasoconstric-
tion in cirrhotic rat livers.8
(3) Thromboxanes A2
Our recent study using the single-photon emission
computed tomography/positron emission tomography/
computed tomography (SPECT/PET/CT)-based evaluation
revealed the increased hepatic Kupffer cell activity and mass
in NASH-cirrhotic rats.10,12 However, cumulative studies also
displayed that increased local production of thromboxanes A2
is also the main factor for the increased IHR in cirrhosis.5 In
cirrhosis, activated Kupffer cells can produce a large amount
of hepatic thromboxanes A2 in livers.
52 Moreover, a positive
feedback regulation loop has been noted between increased
oxidative stress and activated Kupffer cells, which further
stimulate the release of reactive oxygen species (ROS) and
arachidonic acids (Figure 2). Meanwhile, increased ROS can
stimulate Kupffer cells-derived arachidonic acid release.55,56
In hepatic microcirculation, the Kupffer cell-derived throm-
boxanes A2-mediated methoxamine hyper-responsiveness,
increased IHR, and marked portal hypertension in NASH-
cirrhotic rats.
Figure 2. A summary of the systemic endotoxemia and increased oxidative stress-related pathogenic mechanisms for the increased intrahepatic resistance (IHR)
and portal hypertension (PH) in cirrhosis. FGF ¼ fibroblast growth factor; HSCs ¼ hepatic stellate cells; NO ¼ nitric oxide; SECs ¼ sinusoidal endothelial cells;
TXA2 ¼ thromboxane A2; VEGF ¼ vascular endothelial growth factor.
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Cannabinoids are members of the fatty acid amide that bind
with cannabinoid receptors to regulate many physiological and
pathological functions in the body.6,7,57e59 Endocannabinoid
was present in the peripheral and central nervous system to
modulate emotion, memory, pain, muscle tone, and cardio-
vascular function in experimental animals and
humans.6,7,57e59 It has been reported that endocannabinoids-
cannabinoid receptors binding induce the vasorelaxation re-
sponses in cirrhotic splanchnic vessels.60,61 Additionally, the
significant enhancement of anandamide, being the most
extensively investigated endocannabinoids, where vasocon-
strictive response has been reported in cirrhotic livers.6
Accordingly, endocannabinoids have become the potential
targets for the treatment of portal hypertensive syndrome
including increased IHR and associated complications in
cirrhosis.6,7,9,59e63
6. Interaction between endotoxemia and
endocannabinoids in cirrhosis-hepatic microcirculatory
dysfunction
Microcirculatory dysfunction in cirrhotic livers is charac-
terized by an increased adherence of leukocytes to the sinu-
soidal lining (sticky leukocytes) and impaired sinusoidal
perfusion in the chronic endotoxemia state.5,7
Patients with cirrhosis usually have persistent endotoxemia
due to impaired Kupffer cell function. Subsequently, large
amounts of gut-derived bacteria and endotoxin cannot beeffectively removed in cirrhotic animals.64,65 The increased
endotoxemia will promote hepatic fibrogenesis and elevate
portal venous pressure in cirrhosis. Our previous study showed
that intestinal decontamination with oral ciprofloxacin is
effective in the prevention of rebleeding in patients with
cirrhosis who were suffering from acute gastrointestinal
hemorrhage.66 It has been reported that chronic administration
of thalidomide, through inhibition of endotoxin-related ac-
celeration of hepatic fibrogenesis, significantly decreased
portal pressure and IHR in cirrhotic animals (Figure 3).67
It is well-established that endotoxemia will stimulate
macrophage and platelet activity associated with the release of
inflammatory cytokines, tumor necrosis factor (TNF)a, and
thromboxane A2 in cirrhosis.
59,68e70 Further studies have
shown that endotoxin-induced TNFa production is the key
factor to induce liver injury and promote hepatic fibro-
genesis.68,70 Additionally, thromboxane A2 has already proved
to be a potent vasoconstrictor that is involved in the mecha-
nism of increased IHR in cirrhosis.6,54 Anandamide is an
endocannabinoid that demonstrates increasing IHR through
the release of thromboxanes A2 in cirrhotic livers.
6 Our study
also revealed that chronic inhibition of endogenous TNFa by
thalidomide will attenuate the anandamide-mediated vaso-
constriction in cirrhotic livers.68,69
7. Interaction between endotoxemia and
endocannabinoids in cirrhosis-HED
Endotoxemia-related activated endocannabinoid systems
induce HED and subsequently increases IHR in
Therapeutic options for decreasing IHR in the microcirculation of 
cirrhotic livers
Antioxidants (N-acetylcysteine ursodeoxycholic acid or
vitamine E) => improved hepatic endothelial dysfunction
CB receptor antagonism => antihepatic
fibrogenesis and ↓ hepatic
vasoconstrictive hyper-responsiveness
Thalidomide => improved hepatic 
microcirculatory dysfunction & ↓
hepatic vasoconstrictive hyper-
responsiveness
Sorefenib / brivanib=>↓hepatic neo-
angiogenesis, ↓ hepatic venous dys-
regulation
Ciprofloxacin => ↓ endotoxemia & endocannabinoids-
related hepatic microcirculatory dysfunction and hepatic
vasoconstrictive hyper-responsiveness
↓ Intrahepatic 
resistance
Figure 3. Therapeutic options for decreasing intrahepatic resistance (IHR) in the microcirculation of cirrhotic livers. A summary of the potential agents used to
decrease intrahepatic resistance (IHR) in cirrhosis.
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response to vasoconstrictors including endocannabinoids in
hepatic microvasculatures.40,41,48,49 Chronic administration of
ciprofloxacin had also been found to inhibit endotoxemia,
improve HED, and decrease IHR in cirrhotic animals.70 Cip-
rofloxacin has the advantage over the majority of fluo-
roquinolones because it is well-tolerated with low
hepatotoxicity, which had been used to effectively prevent
bacterial infection in patients with cirrhosis after upper
gastrointestinal bleeding.70,71 The same study also observed an
inhibition of the activated hepatic endocannabinoid system in
ciprofloxacin-treated cirrhotic animals, which enhanced the
concepts of endotoxemia and activate hepatic endocannabi-
noid system in cirrhosis.11,58,70 Actually, chronic administra-
tion of the cannabinoid receptor antagonist inhibits the hepatic
inflammation and fibrogenesis in cirrhotic animals.9,63 How-
ever, increased hepatic endocannabinoid production enhanced
the hepatic vasoconstrictive response to ET-1 and subse-
quently increased IHR and portal hypertension in nonalcoholic
steatohepatitis (NASH)-cirrhotic rats.7 Accordingly, an acti-
vated hepatic endocannabinoid system is critical in the
development of hepatic inflammation and fibrogenesis, and
increased IHR in cirrhotic portal hypertension.
8. Interaction between bacterial translocation,
endocannabinoid system, and hemodynamic
abnormalities in cirrhosis
Enteric bacteria overgrowth can stimulate intestinally and
systemically (mainly from MNLs) TNFa production thatresults in increased intestinal bacterial adherence, systemic
bacteremia, and local infection [so called bacterial trans-
location (BT) and SBP] in cirrhosis.72e74 The elevated
circulating TNFa levels have been implicated in the BT-
associated hemodynamic disturbances, including the
splanchnic vasodilatation and hyperdynamic circulation asso-
ciated with cirrhosis.75,76 It has been reported that the
increased TNFa levels, by binding to the TNF receptor, inhibit
phagocytosis of macrophages in cirrhosis.77 Intestinal hyper-
permeability, impaired peritoneal macrophages (PMs) phago-
cytosis, and, BT resulting in increased systemic and local
infection/inflammation such as spontaneous bacterial perito-
nitis (SBP), together with increased TNFa levels, are all
implicated in the pathogenesis of cirrhosis-related
complications.72e76,78,79 Manipulation of cannabinoid re-
ceptors (CB1R and CB2R), which are expressed on the gut
mucosa and PMs, have been reported to modulate intestinal
inflammation and systemic inflammatory cytokines
release.80,81 Especially, CB2R activation reduces oxidative
stress and endotoxin-induced inflammatory cytokines release
in various experimental models of inflammation and sepsis.80
A recent study suggests that CB2R agonist has the potential
to treat BT and various relevant abnormalities through the
inhibition of systemic/intestinal oxidative stress, inflammatory
cytokines, and TNFa releases in cirrhosis.82
In conclusion, the regulation of IHR in cirrhosis depends on
the balance between different factors. The reduction of IHR
can effectively decrease the clinical complications of cirrhotic
portal hypertension. The decrease in these clinical complica-
tions, such as variceal bleeding, will subsequently reduce the
435Y.-Y. Yang, H.-C. Lin / Journal of the Chinese Medical Association 78 (2015) 430e437mortalities in cirrhotic patients. Theoretically, effective treat-
ments will prolong survival of cirrhotic patients by increasing
their chances to receive liver transplantation during long
waiting times. Thus, elucidation of the complicated mecha-
nism in the modulation of hepatic microcirculation is crucial
for the development of therapeutic agents in the future.
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